StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research report sent to investors on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Trading Up 0.5 %
Shares of PULM stock opened at $2.10 on Tuesday. The stock’s fifty day simple moving average is $2.10 and its 200-day simple moving average is $1.99. The company has a market capitalization of $7.67 million, a price-to-earnings ratio of -0.87 and a beta of 0.99. Pulmatrix has a 1-year low of $1.55 and a 1-year high of $2.75.
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share for the quarter. The business had revenue of $1.55 million for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- Comparing and Trading High PE Ratio Stocks
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
